Brief: NKGen Appoints Dr. Anita Fletcher As National Principal Investigator For Phase 2A Troculeucel Trial Evaluating Moderate Alzheimer’S Disease With Adventhealth Orlando As First East Coast Site
19/02/2025 15:05
Feb 19 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN APPOINTS DR. ANITA FLETCHER AS NATIONAL PRINCIPAL
INVESTIGATOR FOR PHASE 2A TROCULEUCEL TRIAL EVALUATING MODERATE
ALZHEIMER’S DISEASE WITH ADVENTHEALTH ORLANDO AS FIRST EAST
COAST SITE
Source text: ID:nGNX9pTy5b
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program